Kohsei Yoh is an expert in Oncology at University of Tsukuba (Japan). Kohsei Yoh has authored 57 publications, the most recent in 2019, and is an investigator in 1 clinical trial. SLR score: 166 (community average: 125). How the SLR is computed.

LeadR Profile

Kohsei Yoh University of Tsukuba Japan
166 ScienceLeadR Reputation 166
Network Map

Oncology

Subspecialties: Pulmonology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1997 - 2025

Source: PubMed

National Cancer Center Hospital East

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 57

Citations

Citations: 1 308 1st author: 10 Last author: 1 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Clinical development of molecular-targeted therapies for non-small cell lung cancer through nationwide genome screening in Japan (LC-SCRUM-Japan)
OpenAlex W2978696466 — cells, molecular targeted therapy, lung, pharmaceutical preparations, neoplasms, carcinoma, non-small-cell lung, genome, lung neoplasms, small cell lung carcinoma, therapeutics
Ann Oncol20191
Clinical utility of precision immunoprofiling and monitoring of the tumour microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: Results from a phase II study for biomarker analysis (EPOC1702)
OpenAlex W2977842980 — flow cytometry, carcinoma, non-small-cell lung, biomarkers
Ann Oncol20190
Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study.
PMID 27476460 — serum, fibrosis, hepatitis, chronic, liver, hepatitis b, hepatitis, viral, human, agglutinins, hepatitis b, chronic, hepatitis
J Viral Hepat201645
T-bet over-expression regulates aryl hydrocarbon receptor-mediated T helper type 17 differentiation through an interferon (IFN)γ-independent pathway.
PMID 27936495 — hydrocarbons, allergy and immunology, cells, receptors, interleukin-6, tretinoin, receptors, aryl hydrocarbon
Clin Exp Immunol20177
Improvement of Quality of Life (QOL) in Osteoporotic Patients by Elcatonin Treatment: A Trial Taking the Participants' Preference into Account.
PMID 23946680 — evidence-based medicine, osteoporosis, analgesia, pain, therapeutics, quality of life
Jpn Clin Med20124

Clinical Studies 1

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 1

By status:

Completed 1

By type:

Interventional 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

LeadR Networks

Main global connection map